Europe Breast Cancer Therapeutics Market size crossed USD 8.2 billion in 2021 and is projected to observe around 7.1% growth rate between 2022 and 2028.

Breast cancer therapeutics encompasses the therapeutic approach used in treatment or management of local recurrence and metastatic spread of the breast cancer. In case of metastatic relapse risk, the breast cancer therapeutics are increasingly preferred in the form of immunotherapy, hormonal therapy, chemotherapy, targeted therapy, or a combination of these therapies.

Get more details on this report - Request Free Sample PDF

Breast cancer therapeutics has emerged as a promising treatment option for patients with breast cancer. There has been a growing adoption of breast cancer medications such as alemtuzumab, trastuzumab, cetuximab, and alkylating among others by healthcare providers. Thus, numerous public and private organizations are emphasizing investment in R&D to offer effective and efficient care delivery for breast cancer treatment.

Medical research charities comprising Cancer Research UK invests over USD 2 billion a year, playing a significant part in improving outcomes for cancer care comprising breast cancer treatment. Further, the AIRC foundation is set up in Italy that raise funds to finance cancer R&D activities all over the country. Similarly, the German Cancer Aid is also actively involved in funding numerous clinical studies to improve prevention, diagnosis, and cancer therapy. Such investments & funding are supporting the scientist & breast cancer research at research centres and clinical training for oncologists to deliver quality treatment for breast cancer patients.

Implementation of breast cancer screening policies and programs to limit the incidence & mortality rates associated with the disease are expected to promote the Europe market growth. The World Health Organization stated that the practice of screening with mammography evidently lowers the mortality from breast cancer. An optimal cancer screening programme with adequate compliance might reduce the breast cancer mortality by minimum 20% in women aged 50 & above. Owing to improved clinical outcomes, majority of the European Union member states run or are initiating population-based screening campaign for breast cancer mammography. The Commission Initiative on Breast Cancer operates to enhance the quality of breast cancer screening, diagnostics, and management across Europe. Further, the regional health agencies also encourage people at risk to undergo breast cancer screening and diagnosis.

Europe Breast Cancer Therapeutics Market, By Therapy

The targeted therapy segment held approximately 70% Europe breast cancer therapeutics market share in 2021. Targeted therapy optimizes the precision of antitumor function and reduces toxicity & damage to normal tissues, play an anchoring role in breast cancer treatment. Technological advancements and increasing research activities in the targeted therapy is further set to drive the segment growth. Currently, the two Phase III clinical studies are in progress to demonstrate the performance of PARP inhibitors against standard chemotherapy.

The OlympiAD trial & the EMBRACA trial evaluated talazoparib and both trials highlighted enhancements in progression-free survival for patients suffering from inherited BRCA gene mutation and metastatic breast cancer. These clinical studies also indicated improvements in quality of life among the patients being administrated with these oral drugs, as compared to chemotherapy. Furthermore, these R&D activities have led to the development & commercialization of precise molecules.

Europe Market, By Country

UK breast cancer therapeutics market accounted for 10% revenue share in 2021 and will reach USD 1.3 billion by 2028. The increasing incidence and mortality associated with breast cancer, and facilitative initiatives implemented by the regulatory authorities in the country is offering business development opportunities to the industry players.

Competitive Industry Landscape

Some of the leading companies involved in the Europe breast cancer therapeutics industry include AstraZeneca, Eli Lilly, & Co., Pfizer, BMS, Novartis, Amgen, Roche, and Merck.

These industry participants are engaged in several strategic initiatives such as mergers & acquisitions, product launch, distribution agreements to maintain their market position. For instance, in July 2020, Novartis received marketing approval in Europe for its Piqray, the first and only targeted medicine commercially available for HR+/HER2- advanced breast cancer with a PIK3CA mutation. This approval helped the company to strengthen and expand its product portfolio in Europe.